ZIOPHARM Oncology Company Profile (NASDAQ:ZIOP)

About ZIOPHARM Oncology (NASDAQ:ZIOP)

ZIOPHARM Oncology logoZIOPHARM Oncology, Inc. is a biopharmaceutical company, which is seeking to develop, acquire and commercialize, on its own or with partners, a portfolio of cancer therapies that address unmet medical needs. The Company is focused on developing products in immuno-oncology that employ gene expression, control and cell technologies to deliver cell- and viral-based therapies for the treatment of cancer and graft-versus-host-disease. It has developed an adenoviral vector, Ad-RTS-IL-12, which is administered intra-tumorally under the control of the RheoSwitch Therapeutic System (RTS) expression platform. Its initial clinical stage product candidate, which is being developed using the immuno-oncology platform is Ad-RTS-IL-12 + veledimex. Ad-RTS-IL-12 + veledimex uses its gene delivery system to produce interleukin-12. As of December 31, 2016, it had completed two Phase II studies evaluating Ad-RTS-IL-12 + veledimex, for the treatment of metastatic melanoma and metastatic breast cancer.

Industry, Sector and Symbol:
  • Sector:
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Symbol: NASDAQ:ZIOP
  • CUSIP: 98973P10
  • Web: www.ziopharm.com
Capitalization:
  • Market Cap: $822.11 million
  • Outstanding Shares: 130,701,000
Average Prices:
  • 50 Day Moving Avg: $7.01
  • 200 Day Moving Avg: $6.46
  • 52 Week Range: $4.45 - $7.99
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -9.68
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $6.49 million
  • Price / Sales: 126.67
  • Book Value: ($0.73) per share
  • Price / Book: -8.62
Profitability:
  • EBIDTA: ($166,930,000.00)
  • Net Margins: -2,276.89%
  • Return on Equity: -364.49%
  • Return on Assets: -32.89%
Debt:
  • Current Ratio: 7.35%
  • Quick Ratio: 7.35%
Misc:
  • Average Volume: 1.33 million shs.
  • Beta: 1.47
  • Short Ratio: 30.7
 

Frequently Asked Questions for ZIOPHARM Oncology (NASDAQ:ZIOP)

What is ZIOPHARM Oncology's stock symbol?

ZIOPHARM Oncology trades on the NASDAQ under the ticker symbol "ZIOP."

How were ZIOPHARM Oncology's earnings last quarter?

ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) released its quarterly earnings data on Monday, May, 1st. The company reported ($0.15) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by $0.03. The firm earned $1.60 million during the quarter, compared to analyst estimates of $1.71 million. ZIOPHARM Oncology had a negative return on equity of 364.49% and a negative net margin of 2,276.89%. The business's quarterly revenue was down 18.8% compared to the same quarter last year. View ZIOPHARM Oncology's Earnings History.

Where is ZIOPHARM Oncology's stock going? Where will ZIOPHARM Oncology's stock price be in 2017?

5 brokerages have issued 12-month target prices for ZIOPHARM Oncology's stock. Their forecasts range from $5.00 to $23.00. On average, they anticipate ZIOPHARM Oncology's share price to reach $14.00 in the next twelve months. View Analyst Ratings for ZIOPHARM Oncology.

Are investors shorting ZIOPHARM Oncology?

ZIOPHARM Oncology saw a increase in short interest in the month of May. As of May 15th, there was short interest totalling 36,064,112 shares, an increase of 0.3% from the April 28th total of 35,957,421 shares. Based on an average daily trading volume, of 1,550,816 shares, the short-interest ratio is currently 23.3 days. Currently, 30.6% of the company's stock are short sold.

Who are some of ZIOPHARM Oncology's key competitors?

Who are ZIOPHARM Oncology's key executives?

ZIOPHARM Oncology's management team includes the folowing people:

  • Laurence James Neil Cooper M.D., Ph.D., Chief Executive Officer
  • Kevin G. Lafond CPA, Principal Financial Officer, Chief Accounting Officer, Vice President - Finance, Treasurer
  • Caesar J. Belbel, Chief Operating Officer, Executive Vice President, Chief Legal Officer, Secretary
  • Murray Brennan, Non-Executive Lead Independent Director
  • Randal J. Kirk, Director
  • James A. Cannon, Independent Director
  • Wyche Fowler Jr., J.D, Independent Director
  • Timothy McInerney, Independent Director

Who owns ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Third Security LLC (7.43%), Vanguard Group Inc. (5.59%), State Street Corp (3.09%), Morgan Stanley (1.52%), Geode Capital Management LLC (0.78%) and Bank of New York Mellon Corp (0.46%). View Institutional Ownership Trends for ZIOPHARM Oncology.

Who sold ZIOPHARM Oncology stock? Who is selling ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock was sold by a variety of institutional investors in the last quarter, including Quantitative Investment Management LLC, JPMorgan Chase & Co., Goldman Sachs Group Inc., KCG Holdings Inc., TIAA CREF Investment Management LLC, Raymond James Financial Services Advisors Inc., Zurcher Kantonalbank Zurich Cantonalbank and Nationwide Fund Advisors. View Insider Buying and Selling for ZIOPHARM Oncology.

Who bought ZIOPHARM Oncology stock? Who is buying ZIOPHARM Oncology stock?

ZIOPHARM Oncology's stock was acquired by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Morgan Stanley, California Public Employees Retirement System, Iridian Asset Management LLC CT, Piermont Capital Management Inc., Cornerstone Capital Management Holdings LLC., Parametric Portfolio Associates LLC and Creative Planning. View Insider Buying and Selling for ZIOPHARM Oncology.

How do I buy ZIOPHARM Oncology stock?

Shares of ZIOPHARM Oncology can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ZIOPHARM Oncology's stock price today?

One share of ZIOPHARM Oncology stock can currently be purchased for approximately $6.29.


MarketBeat Community Rating for ZIOPHARM Oncology (NASDAQ ZIOP)
Community Ranking:  2.2 out of 5 ( )
Outperform Votes:  112 (Vote Outperform)
Underperform Votes:  142 (Vote Underperform)
Total Votes:  254
MarketBeat's community ratings are surveys of what our community members think about ZIOPHARM Oncology and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ZIOPHARM Oncology (NASDAQ:ZIOP) (?)
Ratings Breakdown: 4 Hold Ratings, 1 Buy Rating
Consensus Rating:Hold (Score: 2.20)
Consensus Price Target: $14.00 (122.58% upside)

Analysts' Ratings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/28/2017Griffin SecuritiesReiterated RatingBuy$23.00N/AView Rating Details
1/12/2017JPMorgan Chase & Co.Reiterated RatingHoldN/AView Rating Details
8/10/2016Wells Fargo & CoUpgradeUnderperform -> Market PerformN/AView Rating Details
7/18/2016MizuhoReiterated RatingNeutral$7.00 -> $5.00N/AView Rating Details
6/2/2016Raymond James Financial, Inc.Initiated CoverageMarket PerformN/AView Rating Details
6/22/2015BMO Capital MarketsDowngradeOutperform -> Market Perform$15.00 -> $10.00N/AView Rating Details
(Data available from 5/30/2015 forward)

Earnings

Earnings History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Earnings by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Earnings History by Quarter for ZIOPHARM Oncology (NASDAQ ZIOP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/1/2017Q1 2017($0.12)($0.15)$1.71 million$1.60 millionViewListenView Earnings Details
11/9/2016Q3 2016($0.11)($0.11)$1.45 million$1.60 millionViewN/AView Earnings Details
8/9/2016Q216($0.11)($1.01)$1.52 million$1.70 millionViewN/AView Earnings Details
5/10/2016Q1($0.08)($0.09)$1.89 million$1.97 millionViewN/AView Earnings Details
2/24/2016Q4($0.07)($0.07)$1.82 million$1.92 millionViewN/AView Earnings Details
11/2/2015Q315($0.13)($0.14)$1.19 million$1.90 millionViewN/AView Earnings Details
8/10/2015Q2($0.22)($0.11)$57.70 million$0.27 millionViewN/AView Earnings Details
5/7/2015($0.13)($0.10)$0.20 million$0.30 millionViewN/AView Earnings Details
2/26/2015Q414($0.14)($0.09)$420.00 million$0.34 millionViewN/AView Earnings Details
10/30/2014Q314($0.12)($0.06)$0.20 million$0.63 millionViewN/AView Earnings Details
8/7/2014Q214($0.17)($0.06)$7.50 million$0.20 millionViewN/AView Earnings Details
5/8/2014Q114($0.10)($0.10)$0.20 million$0.20 millionViewN/AView Earnings Details
3/3/2014Q413($0.15)($0.09)$0.20 million$0.20 millionViewN/AView Earnings Details
10/22/2013Q313($0.17)($0.20)$0.20 millionViewN/AView Earnings Details
8/8/2013Q2 2013($0.24)($0.22)$0.20 million$0.20 millionViewN/AView Earnings Details
3/18/2013Q4 2012($0.29)($0.48)$0.17 million$0.20 millionViewN/AView Earnings Details
11/8/2012Q312($0.28)($0.28)$0.20 million$0.20 millionViewN/AView Earnings Details
8/2/2012($0.23)($0.29)ViewN/AView Earnings Details
5/3/2012($0.22)($0.25)ViewN/AView Earnings Details
2/29/2012($0.23)($0.24)ViewN/AView Earnings Details
11/3/2011($0.28)($0.01)ViewN/AView Earnings Details
8/1/2011($0.23)($0.16)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for ZIOPHARM Oncology (NASDAQ:ZIOP)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.09)($0.09)($0.09)
Q2 20171($0.11)($0.11)($0.11)
Q3 20171($0.09)($0.09)($0.09)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for ZIOPHARM Oncology (NASDAQ:ZIOP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Ownership Percentage: 11.50%
Institutional Ownership Percentage: 41.26%
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Institutional Ownership by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Insider Trades by Quarter for ZIOPHARM Oncology (NASDAQ:ZIOP)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/4/2015Murray BrennanDirectorSell40,000$9.70$388,000.00View SEC Filing  
2/9/2015Randal J KirkDirectorBuy1,440,000$8.75$12,600,000.00View SEC Filing  
10/29/2013Randal J KirkDirectorBuy2,857,143$3.50$10,000,000.50View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for ZIOPHARM Oncology (NASDAQ:ZIOP)
Latest Headlines for ZIOPHARM Oncology (NASDAQ:ZIOP)
Source:
DateHeadline
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Receives Consensus Recommendation of "Hold" from Analysts
www.americanbankingnews.com - May 26 at 10:14 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : May 26, 2017
finance.yahoo.com - May 26 at 9:15 AM
reuters.com logoBRIEF-CVI Investments reports 6.8 pct passive stake in Ziopharm Oncology
www.reuters.com - May 22 at 7:48 PM
globenewswire.com logoZIOPHARM Oncology Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma to be Presented at ... - GlobeNewswire (press release)
globenewswire.com - May 18 at 8:21 AM
streetinsider.com logoZiopharm Oncology (ZIOP) Announces Results of Ad-RTS-hIL-12 + Veledimex in Recurrent Glioblastoma Presented at ASCO
www.streetinsider.com - May 17 at 11:38 PM
finance.yahoo.com logoETFs with exposure to ZIOPHARM Oncology, Inc. : May 15, 2017
finance.yahoo.com - May 15 at 7:54 PM
nasdaq.com logoZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock - Nasdaq
www.nasdaq.com - May 12 at 3:15 PM
finance.yahoo.com logoZIOPHARM Oncology Announces Pricing of $50 Million Follow-On Offering of Common Stock
finance.yahoo.com - May 12 at 3:15 PM
finance.yahoo.com logoZiopharm Oncology's stock tumbles after stock offering prices at deep discount
finance.yahoo.com - May 12 at 3:15 PM
finance.yahoo.com logoZiopharm Prices Secondary Offering
finance.yahoo.com - May 12 at 3:15 PM
americanbankingnews.com logo$1.59 Million in Sales Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter
www.americanbankingnews.com - May 10 at 10:52 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. breached its 50 day moving average in a Bearish Manner : ZIOP-US : May 9, 2017
finance.yahoo.com - May 9 at 8:49 PM
americanbankingnews.com logoZacks: Analysts Expect ZIOPHARM Oncology Inc. (ZIOP) to Announce -$0.13 EPS
www.americanbankingnews.com - May 8 at 2:24 PM
americanbankingnews.com logoGriffin Securities Weighs in on ZIOPHARM Oncology Inc.'s Q2 2017 Earnings (ZIOP)
www.americanbankingnews.com - May 8 at 7:11 AM
finance.yahoo.com logoETFs with exposure to ZIOPHARM Oncology, Inc. : May 4, 2017
finance.yahoo.com - May 5 at 5:40 AM
finance.yahoo.com logoZIOPHARM Oncology, Inc. :ZIOP-US: Earnings Analysis: Q1, 2017 By the Numbers : May 3, 2017
finance.yahoo.com - May 3 at 7:07 PM
reuters.com logoBRIEF-ZIOPHARM announces FDA acceptance of IND for CD33-specific CAR-T cell therapy
www.reuters.com - May 3 at 9:32 AM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Receives Daily Media Sentiment Score of 0.11
www.americanbankingnews.com - May 2 at 10:38 AM
finance.yahoo.com logoEdited Transcript of ZIOP earnings conference call or presentation 1-May-17 8:30pm GMT - Yahoo Finance
finance.yahoo.com - May 2 at 8:03 AM
finance.yahoo.com logoZIOPHARM Oncology Reports First Quarter 2017 Financial Results and Provides Update on Recent Activities - Yahoo Finance
finance.yahoo.com - May 2 at 8:03 AM
finance.yahoo.com logoEdited Transcript of ZIOP earnings conference call or presentation 1-May-17 8:30pm GMT
finance.yahoo.com - May 2 at 8:03 AM
finance.yahoo.com logoZIOPHARM Oncology Announces FDA Acceptance of IND for CD33-Specific CAR-T Cell Therapy Targeting Relapsed/Refractory Acute Myeloid Leukemia
finance.yahoo.com - May 2 at 8:03 AM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Posts Quarterly Earnings Results, Misses Estimates By $0.06 EPS
www.americanbankingnews.com - May 1 at 11:40 PM
finance.yahoo.com logoInvestor Network: ZIOPHARM Oncology, Inc. to Host Earnings Call
finance.yahoo.com - May 1 at 7:51 PM
marketbeat.com logoZiopharm reports 1Q loss
marketbeat.com - May 1 at 4:33 PM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Receives Average Rating of "Hold" from Analysts
www.americanbankingnews.com - May 1 at 1:34 PM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Getting Somewhat Favorable Media Coverage, Study Finds
www.americanbankingnews.com - April 29 at 9:16 AM
globenewswire.com logoZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1 ... - GlobeNewswire (press release)
globenewswire.com - April 26 at 5:27 PM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Upgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - April 26 at 4:36 PM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Given News Sentiment Rating of 0.30
www.americanbankingnews.com - April 26 at 8:13 AM
finance.yahoo.com logoZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1 ... - Yahoo Finance
finance.yahoo.com - April 24 at 8:16 AM
feeds.benzinga.com logoZIOPHARM Oncology to Host First-Quarter 2017 Financial Results and Corporate Update Conference Call on May 1, 2017 at 4:30 p.m. ET
feeds.benzinga.com - April 24 at 7:19 AM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Given News Impact Score of -0.06
www.americanbankingnews.com - April 23 at 11:49 AM
nasdaq.com logoNoteworthy Friday Option Activity: SYNT, ZIOP, TSLA
www.nasdaq.com - April 21 at 10:22 PM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Earning Somewhat Favorable News Coverage, Analysis Finds
www.americanbankingnews.com - April 19 at 9:08 AM
americanbankingnews.com logo-$0.12 EPS Expected for ZIOPHARM Oncology Inc. (ZIOP) This Quarter
www.americanbankingnews.com - April 17 at 4:28 PM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Short Interest Down 0.1% in March
www.americanbankingnews.com - April 15 at 2:46 PM
americanbankingnews.com logoZIOPHARM Oncology (ZIOP) Earns Daily News Sentiment Score of 0.25
www.americanbankingnews.com - April 14 at 8:44 AM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - April 6 at 2:14 PM
globenewswire.com logoIntrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next ...
globenewswire.com - April 4 at 5:26 AM
us.rd.yahoo.com logoIntrexon, ZIOPHARM and Merck KGaA, Darmstadt, Germany Advancing Next-Generation Non-Viral CAR-T Platform Empowered by Membrane-Bound IL-15 Under RheoSwitch Therapeutic System® Control
us.rd.yahoo.com - April 4 at 5:26 AM
globenewswire.com logoZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications - GlobeNewswire (press release)
globenewswire.com - March 28 at 8:02 AM
investopedia.com logoFDA Allows Ziopharm Brain Cancer Drug Trial (ZIOP)
www.investopedia.com - March 27 at 8:07 PM
biz.yahoo.com logoZIOPHARM ONCOLOGY INC Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
us.rd.yahoo.com - March 27 at 8:07 PM
americanbankingnews.com logoZIOPHARM Oncology Inc. (ZIOP) Sees Large Decrease in Short Interest
www.americanbankingnews.com - March 27 at 8:05 AM
reuters.com logoBRIEF-Ziopharm appoints Amy Trevvett vice president of investor relations and corporate communications
www.reuters.com - March 27 at 8:00 AM
finance.yahoo.com logoZIOPHARM Appoints Amy Trevvett Vice President of Investor Relations and Corporate Communications
finance.yahoo.com - March 27 at 8:00 AM
finance.yahoo.com logoImplied Volatility Surging for ZIOPHARM Oncology (ZIOP) Stock Options
finance.yahoo.com - March 20 at 6:52 PM
prnewswire.com logoTechnical Reports on Biotech Stocks -- ZIOPHARM Oncology, Aurinia Pharma, Arena Pharma, and Marinus Pharma - PR Newswire (press release)
www.prnewswire.com - March 1 at 8:02 AM
nasdaq.com logoNotable Friday Option Activity: ZIOP, JWN, EROS
www.nasdaq.com - February 25 at 4:39 AM

Social

Chart

ZIOPHARM Oncology (ZIOP) Chart for Tuesday, May, 30, 2017

This page was last updated on 5/30/2017 by MarketBeat.com Staff